Diabetes, TZDs, and Bone: A Review of the Clinical Evidence
Evidence from rodent and in vitro models suggests that activation of PPAR-γ by thiazolidinediones (TZDs) causes increased bone marrow adiposity and decreased osteoblastogenesis, resulting in bone loss. TZDs are prescribed for the treatment of diabetes, providing an opportunity to determine whether P...
Saved in:
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2006-01-01
|
| Series: | PPAR Research |
| Online Access: | http://dx.doi.org/10.1155/PPAR/2006/24502 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|